Hey Neurohacker,

Before we dive in — a quick but genuine thank you. With 55% of you opening The Neurocircuit every single week, you're not just a subscriber, you're an active part of this community. That means everything to us.

This week, we're asking you to help us go further — together:

🧠 Refer a Neurohacker → Know someone who geeks out over brain optimization, performance, or neuroscience? Send them our way. Refer a Neurohacker 🦾

⚡ Join the Community Challenge → This week's challenge is live. Participate, share your results, and let's grow as a community — because the bigger we get, the bigger the things we can Hack the Neuron on together. Join the Challenge 🧎

📬 Help Shape The Neurocircuit → Got feedback? A topic you want covered? Something we can do better? Tell us. This newsletter is built for you, so help us build it right. Send Feedback 🧑‍💻

And before we get into this week's content — a quick word from our partner:

✦ This Week's Partner: The DeepView

Neurotechnology News | March 7–13, 2026

Let's cut through the noise.

This week, a randomized trial validated accelerated deep transcranial magnetic stimulation (dTMS) for depression and a peer-reviewed Nature paper reframed how noninvasive modalities must work together. Over $94 million flooded into Chinese brain-computer interface (BCI) startups, and China's regulator issued the world's first commercial approval for an invasive BCI. Bottom line: the global BCI race just got a new front-runner — and the finish line is no longer about science alone.

China's National Medical Products Administration (NMPA) granted commercial marketing authorization to Neuracle Medical Technology for its NEO epidural BCI system — the first invasive BCI anywhere in the world authorized for commercial sale, not just clinical investigation. The device uses 8 epidural electrocorticography (ECoG) contacts and battery-free wireless power to decode grasp intent in spinal cord injury patients, with trials spanning 36 surgeries and a reported F1-score of 0.91 for grasp detection. This is not primarily an algorithm milestone — it is a systems-integration milestone: approval covers the complete product stack, from implantable hardware and wireless telemetry to decoding software, external actuator, and clinical workflow. The approval lands inside a broader policy push: BCI appeared for the first time in China's 2026 Government Work Report as a designated "future industry," and China now has more than 10 active invasive BCI trials with plans to enroll over 50 patients nationwide this year. As Yao Dezhong, Director of the Sichuan Institute of Brain Science and National People's Congress delegate, told Reuters on March 7: "China is actually making very fast progress in this area now. In fact, Musk's direction is basically achievable domestically." What it signals architecturally is that regulators will greenlight invasive BCIs when the use case is tightly scoped, patient selection is defined, and the device can be positioned as a durable medical system rather than a lab prototype. For every BCI team still in trials, the benchmark has now shifted from "does it work?" to "can it be manufactured, serviced, and post-market monitored at scale?"

Published: March 13, 2026
Read more ➡️ BioSpace / SSRN

A multisite, blinded, randomized non-inferiority trial (N=104; 89 completers) published in Brain Stimulation found BrainsWay's SWIFT™ accelerated deep transcranial magnetic stimulation (dTMS) protocol achieved an 87.8% response rate and 78.0% remission rate — statistically non-inferior to the standard 20-session protocol — while compressing acute-phase treatment to just 6 half-day clinic visits. The SWIFT protocol applies theta-burst stimulation via the H1 deep coil at 110% resting motor threshold, requires no functional MRI or neuronavigation, and achieved a median time to remission of 21 days vs. 28 days for standard treatment (p=0.0324).

💡 Big Picture: Removing neuronavigation from the required stack means any existing TMS clinic can adopt SWIFT without capital equipment upgrades — the scalability bottleneck just shifted from hardware procurement to insurance reimbursement coverage, where three major U.S. payers (Premera, Highmark, Cigna/Evernorth) have already moved.

Published: March 10, 2026
Read more ➡️ MedicalXpress / Nature

A Carnegie Mellon University team used concurrent EEG source localization to compare low-intensity transcranial focused ultrasound (tFUS) alone, transcranial direct current stimulation (tDCS) alone, and a combined transcranial electro-acoustic stimulation condition in resting-state humans. Only the combined condition produced strong, spatially specific cortical activation — consistent with a subthreshold-summation mechanism in which neither modality independently crosses the activation boundary.

💡 Big Picture: This reframes noninvasive neuromodulation design as a compositional engineering problem: future systems may require co-designed waveform scheduling, inter-modality coupling models, and artifact-aware EEG validation layers rather than independent single-modality hardware — a structural shift in how the stack gets tested, characterized, and submitted to regulators.

Published: March 13, 2026
Read more ➡️ Scientific American / Xinhua

China's NMPA approved Neuracle Medical Technology's NEO for commercial sale — the first such authorization for an invasive BCI anywhere in the world — targeting quadriplegic patients aged 18–60 with cervical spinal cord injuries. The coin-sized, battery-free epidural device uses 8 ECoG contacts and near-field inductive wireless power; across 36 implant surgeries in clinical trials, grasp detection reached an F1-score of 0.91 with no penetration of brain tissue.

💡 Big Picture: Neuracle reached commercial clearance by making a deliberate architectural tradeoff — 8 epidural contacts instead of 1,024 intracortical electrodes — trading signal bandwidth for longevity, surgical simplicity, and regulatory tractability; the lesson for the field is that a scoped, shippable system beats an optimal system still in trials.

Published: March 13, 2026
Read more ➡️Yahoo!Finance / krASIA

Shanghai-based StairMed Technology closed a RMB 500 million (~$72.6M) round led by Alibaba Group, bringing total funding over the past 12 months to over RMB 1.1 billion (~$160M). The company recently completed its first clinical implantation of a 256-channel wireless BCI using a proprietary surgical robot and plans multicenter registration trials targeting ~40 patients in 2026.

💡 Big Picture: Alibaba's entry — a platform company, not a medtech fund — signals China's tech giants have categorized BCI as infrastructure rather than a niche medical device play; StairMed's robot-assisted implantation strategy directly parallels Neuralink's R1 robot, suggesting precision surgical automation is becoming a table-stakes component of any high-channel-count BCI system.

Published: March 12, 2026
Read more ➡️ TNW / MarketScreener

Gestala Technology raised CN¥150 million (~$21.6M) in an angel round co-led by Guosheng Capital and Dalton Venture, with reported investor commitments exceeding $58M total; the round was framed as oversubscribed. The company targets chronic pain as its lead indication — early internal trials reportedly showed single-session pain score reductions of ~50% lasting 1–2 weeks — and is building a proprietary "Ultrasound Brain Bank" clinical dataset for AI-driven neural decoding.

💡 Big Picture: Ultrasound BCI's core engineering challenge is not whether it can modulate neural tissue — it's whether teams can build reproducible per-user calibration pipelines that account for skull variability, transducer coupling, and positioning repeatability; that is where the competitive moat will form, not in the transducer hardware itself.

Published: March 12, 2026
Read more ➡️ MassDevice / BusinessWire

Dutch-German neuroadaptive AI company Zander Labs announced U.S. market expansion for its passive BCI (pBCI) platform, which continuously monitors cognitive states — workload, focus, error recognition, and intent — from EEG without requiring any deliberate user input. The company holds a $33M German government contract for pBCI prototype development and is seeking defense, mobility, robotics, and healthcare partners on the U.S. West Coast.

💡 Big Picture: Passive BCIs sidestep the active-engagement bottleneck entirely, positioning them as the neurotech category most likely to reach non-clinical mass deployment first — but achieving sufficient signal-to-noise reliability outside controlled environments (high-vibration, high-motion operational settings) remains the fundamental unsolved engineering problem.

Published: March 13, 2026
Read more ➡️ Geneva Science and Diplomacy Anticipator / OHCHR

The UN Human Rights Council's 61st session (running February 23–March 31, 2026) called on member states to submit input for the UN Secretary-General's report on neurotechnology in the administration of justice; the HRC Advisory Committee separately began developing guidelines under Resolution 58/6, with both outputs targeted for mid-2026. The GESDA synthesis report released this week identified BCIs, cognitive enhancement, and neuro-AI integration as the technologies most likely to test existing human rights frameworks in the near term.

💡 Big Picture: The HRC's strategy of applying existing human rights law rather than drafting new "neurorights" legislation could move faster through ratification — and critically, consumer EEG devices capable of lie detection or cognitive risk assessment in courtrooms do not require implants, meaning governance timelines may arrive before most BCI builders have even filed for FDA clearance.

This week's news surfaces a question the field hasn't had to answer until now: what does "evidence of effect" actually mean across neural interfaces that operate on completely different physical principles — and who gets to define it? Neuracle's NEO cleared the NMPA with 8 epidural contacts, a tightly scoped use case, and a full end-to-end product stack — a model built around reliability engineering and defined clinical boundaries. In the same week, the Carnegie Mellon tFUS + tDCS paper showed that noninvasive neuromodulation effects may only emerge from the interaction between two concurrent modalities, meaning neither can be independently validated against current single-modality regulatory templates. These two approval realities — one for a scoped invasive system, one implied for a multi-modal noninvasive stack — are not reconcilable under the same framework. Are we heading toward harmonized interface contracts with shared measurement endpoints, artifact reporting standards, and wireless security baselines? Or modality-specific regulatory silos that make cross-stack comparisons impossible for the next decade? The internet's early standards wars settled on "worse is better" pragmatism over elegant protocols. The BCI field may be approaching the same fork.

If you’re a decision maker at your company, you need to be on the bleeding edge of, well, everything. But before you go signing up for seminars, conferences, lunch ‘n learns, and all that jazz, just know there’s a far better (and simpler) way: Subscribing to The Deep View.

This daily newsletter condenses everything you need to know about the latest and greatest AI developments into a 5-minute read. Squeeze it into your morning coffee break and before you know it, you’ll be an expert too.

Subscribe right here. It’s totally free, wildly informative, and trusted by 600,000+ readers at Google, Meta, Microsoft, and beyond.

Neurotech moves faster when people share what they're building. Whether you're working on a DIY biosignal project, following a clinical trial, or just had an idea you can't shake — put it out there. The best thinking in this field happens in the open.

Why bother? This community is small enough that your work actually gets seen, and focused enough that the people seeing it are the right ones. One post can get you a collaborator, a citation, or a conversation that changes the direction of a project.

The NeuroCircuit grows entirely through word of mouth. If this issue was worth your time, pass it to one person it would also be worth.

Share your referral link and earn:

Every issue gets shaped by what readers actually find useful. If something landed well, felt thin, or missed the mark entirely — say so. This is a small, focused publication and your feedback has a direct line to next week's issue.

What's worth a minute of your time: